Navigation Links
Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance
Date:10/30/2008

t cash

provided by operating activities:

Depreciation and amortization 26,217 25,518

Amortization of premiums on investments, net of

accretion of discounts 5,118 3,379

Stock-based compensation charges 15,012 14,487

Stock-based compensation income tax benefits 3,025 2,031

Excess tax benefit from stock-based compensation (2,510) (13,055)

Gain on sale of stock holdings of Molecular

Profiling Institute, Inc. (1,600) -

Impairment charges 5,086 -

Loss on disposal of property and equipment 38 202

Changes in assets and liabilities:

Accounts receivable 11,403 (15,861)

Inventories (4,270) 2,660

Prepaid expenses 7,060 (6,538)

Other current assets (2,255) (2,756)

Other long term assets (510) (930)

Accounts payable 7,381 1,116

Accrued salaries and employee benefits 4,922 6,328

Other accrued expenses 96 5,343

Income tax payable 2,926 (14,544)

Deferred revenue (3,399) 202

Deferred income tax (961) 794

Deferred rent (10) (88)

Deferred compensation plan liabilities 436 544

Net cash provided by operating activities 159,019 74,560

Investing activities:

Proceeds from sales a
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Gen-Probe Announces Webcasts of Three Upcoming Investor Events
2. Gen-Probe to Webcast Two Upcoming Investor Presentations
3. Gen-Probe Announces Webcast of First Quarter 2008 Earnings Conference Call
4. Gen-Probe to Webcast Presentation at Leerink Swann Molecular Diagnostics Conference
5. Gen-Probe to Webcast Presentation at Deutsche Bank Small- and Mid-Cap Growth Conference
6. Gen-Probe to Webcast Presentation at 26th Annual JPMorgan Healthcare Conference
7. Gen-Probe to Webcast Presentation at NASDAQ 20th Investor Program
8. Jorgine Ellerbrock Joins Gen-Probe as Senior Vice President, Operations
9. 3M, Gen-Probe to Discontinue Molecular Food Testing Collaboration
10. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
11. Nuvelo Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... London, UK (PRWEB) May 22, 2015 ... the leading treatment option for chronic obstructive pulmonary ... UK’s GlaxoSmithKline plc and AstraZeneca plc as well ... for market share and position. But will market ... from the already well-entrenched products to completely new ...
(Date:5/22/2015)... Carnegie Science Center and Allegheny ... to develop BodyTech, a dynamic, three-pronged health and science ... new exhibit at the Science Center called BodyWorks, the ... traveling science show, Anatomy Adventure, which will hit the ... to explore a wide range of topics surrounding health ...
(Date:5/22/2015)... Power Systems is proud to announce the sponsorship ... Drobeck is in his second year of racing in the ... Missoula Fire Department in Missoula, MT. He entered the triathlon ... his career, he has had 15 1st Place finishes. In ... finishes in all seven of his 2014 races, including two ...
(Date:5/22/2015)... May 22, 2015 The ... Dental announces that they are now offering complimentary ... other dental treatments. At consultations, patients can discuss ... regarding what certain treatments can achieve and whether ... during this initial appointment. If treatments are chosen, ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 A ... at the American Society of Clinical Oncology (ASCO)’s ... improved survival rates for those patients who received ... regimen of pemetrexed/cisplatin. Bevacizumab (Avastin® Genentech, Inc.) is ... and it is already routinely used to treat ...
Breaking Medicine News(10 mins):Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4Health News:West Hollywood Dental Office, Sunset Plaza Dental is Now Offering Complimentary Consultations 2Health News:Mesothelioma Research Organization Excited About Imminent Improvement to Standard of Care 2
... Pure Power Mouthguard ... , ... December 4, 2009 -- Miami dentist Dr. H.A. Nassery contributes to local athletic ... to patients. He successfully diagnosed and treated Ashley Kimmel, a student at Miami Country Day ...
... 2-D images represent, researchers say , FRIDAY, Dec. 4 ... monkeys they know, proving that they can both detect ... them before, researchers report. , The study also shows ... a photograph, the scientists authors noted. , The findings, ...
... However, benefits are not clear enough to recommend its ... News) -- Cancer patients, glaucoma patients and others can ... shows that it can help multiple sclerosis (MS) patients ... hallmark of the debilitating autoimmune disease. , "The therapeutic ...
... , LOS ANGELES, Dec. 4 Yogen Fruz , the ... holiday themed "NUmixes" -- Yog-Nog and Mint Chocolate ... unveiled at Yogen Fruz stores across North America. Yogen Fruz,s low-calorie ... dessert alternative to indulge in this holiday season. , ...
... , BOSTON and HOUSTON, Dec. 4 AES Annual ... announced today that Vagus Nerve Stimulation (VNS) Therapy , the ... will be featured in 14 presentations at the American Epilepsy ... Hynes Convention Center in Boston, Massachusetts. , Robert Elliott, ...
... , ... InhibOx, a leading developer of novel ... MolPort, an innovator in rare chemical trading.,MolPort focuses on developing rare ... we provide this database and its updates to computational chemists at ...
Cached Medicine News:Health News:Miami Dentist Dr. H.A. Nassery Treats Local Teen Golf Star and Helps Improve Her Performance 2Health News:Review Finds Marijuana May Help MS Patients 2Health News:Review Finds Marijuana May Help MS Patients 3Health News:Yogen Fruz Introduces New Holiday Flavors: Yog-Nog and Mint Chocolate Chip 2Health News:NYU Langone Medical Center Study Shows VNS Therapy is a Safe and Effective Treatment for Refractory Epilepsy 2Health News:NYU Langone Medical Center Study Shows VNS Therapy is a Safe and Effective Treatment for Refractory Epilepsy 3Health News:InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery 2Health News:InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery 3
(Date:5/22/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... of the results of the Company,s 72-patient, placebo-controlled ... drops) for the treatment of dry eye patients ... ) model.  The exploratory study was completed in ... disseminated by the Company in a press release, ...
(Date:5/22/2015)... -- According to a new market research ... Services), by Test Type (Indirect, Enzyme-based, Reactive Oxygen Species ... Users - Global Forecast to 2020", published by MarketsandMarkets, the ... $736.85 Million by 2020 from $452.36 Million in 2015, ... Browse 71 market data Tables and 90 Figures spread ...
(Date:5/22/2015)... , May 22, 2015   InspireMD, Inc. ... stent embolic protection systems ("EPS"), today announced that its CGuard ... lead by principle investigator Prof. Piotr Musialek , at ... Paris, France . PARADIGM, an ... R cutaneous c A roti D revascularization I ...
Breaking Medicine Technology:Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 4InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4
... BLUE BELL, Pa., Feb. 2, 2011 Inovio Pharmaceuticals, ... in the development of therapeutic and preventive vaccines against ... a scientific paper in the journal Human Vaccines ... of Inovio,s SynCon™ DNA vaccine for prostate cancer targeting ...
... LIONVILLE, Pa., Feb. 1, 2011 West Pharmaceutical Services, Inc. ... attend the UBS 21st Annual Global Healthcare Services Conference in ... business and outlook on Tuesday, February 8, 2011 at 1:00 ... Company,s presentation, as well as a copy of the presentation ...
Cached Medicine Technology:Inovio Pharmaceuticals' Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial 2Inovio Pharmaceuticals' Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial 3Inovio Pharmaceuticals' Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial 4Inovio Pharmaceuticals' Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial 5
The CryoSurgery console is the control center for CryoCath's surgical probe. It is a modular system made up of a console control unit and a tank dolly system. The system can be used as a unit or in s...
... developed a minimally invasive cryocatheter to ... delivers a very high level of ... site precision, minimal tissue disruption, and ... ,Freezor is a flexible, single-use, minimally ...
The Valve Mapper Steerocath-Dx has a unique "peanut" shaped tip. It is designed to conform to the anatomy during mapping procedures. Both 8F/8mm and 8F/6mm tips are available....
... The PORTERFIELD catheter incorporates six electrodes which ... from a single catheter. Positioned in the ... while recording atrial electrograms. The catheter may ... apex for atrial recording and ventricular pacing ...
Medicine Products: